Table 3. Medications to treat ARD associated with poor and negative seroconversion reactions to the BNT162b2 vaccine.

Ab: Antibody; ARD: Autoimmune rheumatic disease; Cs-DMARDs: Conventional synthetic disease-modifying antirheumatic drugs; IL6-i: Interleukin 6 inhibitor; JAK-i: Janus kinase inhibitor; MTX: Methotrexate; MTXM: Methotrexate monotherapy; TNF-i: Tumor necrosis factor inhibitor; NA: Not applicable.

Medications	Seropositive Ab titre ≥ 0.8  (n = 103)	Negative seroconversion Ab titre < 0.8  (n = 7)	P-value	Seropositive Ab titre ≥ 132 (n = 89)	Poor seroconversion Ab titre < 132  (n = 21)	P-value
MTXM	15 (14.6)	0 (0)	0.590	14 (15.7)	1 (4.8)	0.294
MTX combination	48 (46.6)	2 (28.6)	0.452	40 (44.9)	10 (47.6)	0.825
Hydroxychloroquine	18 (17.5)	2 (28.6)	0.609	18 (20.2)	2 (9.5)	0.353
Sulfasalazine	6 (5.8)	0 (0)	1.000	6 (6.7)	0 (0)	0.593
Leflunomide	4 (3.9)	0 (0)	1.000	2 (2.2)	2 (9.5)	0.164
Cs-DMARDs only	26 (25.2)	0 (0)	0.195	25 (28.1)	1 (4.8)	0.023
Mycophenolate	1 (1)	2 (28.6)	0.010	1 (1.1)	2 (9.5)	0.093
TNF-i	46 (44.7)	0 (0)	0.040	37 (41.6)	9 (42.9)	1.000
TNF-i monotherapy	24 (23.3)	0 (0)	0.343	22 (24.7)	2 (95)	0.154
JAK-i	12 (11.7)	0 (0)	1.000	9 (10.1)	3 (14.3)	0.696
Rituximab	13 (12.6)	7 (100)	0.000	12 (13.5)	8 (38.5)	0.009
IL6-i	7 (6.8)	0 (0)	1.000	6 (6.7)	1 (4.8)	1.000
Glucocorticoid	4 (3.9)	5 (714)	0.000	2 (2.2)	7 (33.3)	0.000